Marie Wikström Lindholm
Chief Tech/Sci/R&D Officer at SILENCE THERAPEUTICS PLC
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Craig Tooman | M | 58 | 3 years | |
| Rhonda L. Hellums | F | 52 | 3 years | |
| David Lemus | M | 61 | 6 years | |
| Gem Hopkins | M | - | 4 years | |
| Steven Romano | M | 64 | 5 years | |
| Richard Geary | M | 66 |
Oligonucleotide Therapeutics Society, Inc.
 Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | - |
| Jeffrey Foy | M | - |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | - |
| J.P. Gabriel | M | - | 1 years | |
| Jonathan K. Watts | M | - |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | - |
| Frank Rigo | M | - |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | - |
| Paloma H. Giangrande | M | - |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | - |
| Steven Dowdy | M | - |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | - |
| Shalini Andersson | M | - |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | - |
| Annemieke Aartsma-Rus | M | - |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | - |
| Eric Fink | M | - | 2 years | |
| Laura Sepp-Lorenzino | M | 63 |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | - |
| Isabel Aznarez | M | 52 |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | 5 years |
| Linnea Corwin Elrington | F | - | 7 years | |
| Eric Floyd | M | 62 | 5 years | |
| Roland Andersson | M | 69 |
University of Lund
| 24 years |
| Takanori Yokota | M | - |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | - |
| Marc M. Lemaître | M | - |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | - |
| Michael Davidson | M | 67 | 3 years | |
| James Ede-Golightly | M | 44 | 5 years | |
| Bengt Arvid Westrin | M | 66 |
University of Lund
| 25 years |
| Ian MacLachlan | M | - |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | - |
| Iain Ross | M | 71 | 5 years | |
| Curtis Rambaran | M | - | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Stephen Parker | M | 65 | 6 years | |
| Andrew Richards | M | 64 | 3 years | |
| David J. Ellam | M | - | 3 years | |
| Ahmad Mortazavi | M | 53 | 6 years | |
| Mark Rothera | M | 61 | 2 years | |
| Robert Quinn | M | 41 | 4 years | |
| Alistair Gray | M | 75 | 9 years | |
| Annalisa Jenkins | M | 58 | 1 years | |
| Karl Hampus Jakobsson | M | 45 |
University of Lund
| 4 years |
| Måns Nicklas Lidgren | M | 47 |
University of Lund
| 5 years |
| Giles Campion | M | 69 | 4 years | |
| David Solomon | M | 63 | 2 years | |
| Jorgen Wittendorff | M | - | 4 years | |
| John Strafford | M | - | 5 years | |
| Michael Green | M | - |
University of Lund
| 4 years |
| Laura Roca-Alonso | M | - | 15 years | |
| Peter Montgomery | M | 50 |
University of Lund
| 5 years |
| Carl-Johan Rijpma | M | 49 |
University of Lund
| 2 years |
| Jan Talts | M | 59 |
University of Lund
| 4 years |
| Louise Öfverström | F | 49 |
University of Lund
| 2 years |
| Cajsa Wramdemark | F | 47 |
University of Lund
| 1 years |
| Susanne Bylund | F | - |
University of Lund
| 6 years |
| Felix Erhardt | M | 46 |
University of Lund
| 4 years |
| Susan Gustafsson | F | 51 |
University of Lund
| 4 years |
| Åsa Schiött | M | - |
University of Lund
| 3 years |
| Torsten Hoffmann | M | 57 | 1 years | |
| Karl Helge Tore Lidgren | M | 76 |
University of Lund
| 20 years |
| Sofia Svensson | F | 46 |
University of Lund
| 5 years |
| Christian Kjellman | M | 57 |
University of Lund
| 3 years |
| Peter Sandin | M | 57 |
University of Lund
| 2 years |
| Patrik Romberg | M | 58 |
University of Lund
| 2 years |
| Anna Haupt | F | - |
University of Lund
| 5 years |
| Johannes Swartling | M | 52 |
University of Lund
| 3 years |
| Staffan Skogvall | M | 61 |
University of Lund
| 3 years |
| Inga Sarah Maria Fredriksson | M | 56 |
University of Lund
| 3 years |
| Fredrik Ekström | M | - |
University of Lund
| 1 years |
| Björn Brodén | M | - |
University of Lund
| 1 years |
| Bernt Ove Mikael Johannesson | M | - |
University of Lund
| 3 years |
| Kirstin Kriz | M | 49 |
University of Lund
| 3 years |
| Alison Gallafent | F | - | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 28 | 41.18% |
| Sweden | 27 | 39.71% |
| United States | 13 | 19.12% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Marie Wikström Lindholm
- Personal Network
